Lyra Therapeutics Stock (NASDAQ:LYRA)

Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.